HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Estee Lauder

This article was originally published in The Rose Sheet

Executive Summary

Net sales for fiscal third quarter (ending May 31) to grow 8%- 9% on constant currency basis versus year-ago period, firm predicts in refined sales and earnings outlook March 15. Lauder previously had forecast an 8%-10% gain. U.S. sales growth expected to be in low- to mid-single digits while double-digit growth predicted in Europe, the Middle East and Africa and Asia/Pacific regions, firm notes. Hair care to grow double digits, strong growth expected in makeup and skin care categories, while fragrance sales likely will remain flat, firm says. Net sales for year to increase along company's historical growth pattern of 8%-10% in constant currency. Lauder continues to be cautious that U.S. economic conditions are creating softer retail sell-through that may affect company results for second half 2001

Latest Headlines
See All
UsernamePublicRestriction

Register

RS009034

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel